Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex (Nasdaq: ENLV) dosed the first U.S. patient in its global, randomized, double-blind, placebo-controlled Phase 2b trial of Allocetra for moderate-to-severe age-related primary knee osteoarthritis.
The study spans the United States, Denmark and Poland, with endpoints focused on pain, function, quality of life and mobility.
Enlivex (Nasdaq: ENLV) received a Nasdaq notice that its ordinary shares failed to meet the $1.00 minimum bid price for 30 consecutive business days, triggering a compliance period.
Enlivex has 180 days, until November 9, 2026, to regain compliance, with a possible additional 180-day extension.
Enlivex (Nasdaq: ENLV) announced that its treasury token RAIN was listed on the HTX cryptocurrency exchange, effective April 29, 2026. The listing expands global accessibility and secondary liquidity for RAIN and follows the company disclosure of 78.8 billion RAIN tokens valued at $567 million as of April 27, 2026.
HTX serves over 160 countries, ranked among top global exchanges, and reported roughly $3.3 trillion cumulative trading volume in 2025.
Enlivex (Nasdaq: ENLV) reported its total RAIN holdings rose to 78,819,756,062 tokens as of April 27, 2026, with an aggregated value of $567 million. Recent purchases were made via partial exercises of an option to buy up to 272,121,212,121 RAIN tokens at $0.0033 per token.
The option expires Dec. 31, 2027, and the stated exercise price is an approximately 55% discount to RAIN’s April 27, 2026 closing price.
Enlivex (Nasdaq: ENLV) will present Phase IIa 3-month and 6-month clinical data for Allocetra at the OARSI 2026 World Congress (April 23-26, 2026) in West Palm Beach.
Posters report statistically significant, clinically meaningful reductions in pain and improved function versus placebo in idiopathic age-related KOA patients ≥60, plus pharmacological data on Allocetra's immunomodulating mechanism.
Enlivex (Nasdaq: ENLV) announced Danish Medicines Agency (DKMA) approval to enroll patients in Denmark for the global Phase 2b trial of Allocetra in age-related moderate-to-severe knee osteoarthritis.
This follows recent FDA clearance; the randomized, double-blind, placebo-controlled study will enroll patients in the United States, Denmark and Poland and is powered to assess pain, function and quality-of-life at three and six months.
Enlivex (Nasdaq: ENLV) announced that Ondo Finance launched ENLVon, a tokenized representation of Enlivex ordinary shares on Ondo Global Markets, enabling non‑U.S. retail and institutional investors to gain economic exposure via digital wallets, fractional holdings, and near‑instant settlement.
The release notes tokenized stocks topped $1 billion on‑chain, and Ondo holds ~61% market share with about $653 million in tokenized stock value across ~265 tokenized securities and ETFs.
Enlivex (Nasdaq: ENLV) reported that the Rain Foundation launched an AI agent-ready OpenClaw interface enabling anyone to create a live prediction market from a single prompt. The Foundation also announced a $5 million grant program to fund developers building on the Rain protocol.
Enlivex noted it is a major holder of RAIN in its treasury and highlighted a protocol mechanism that allocates approximately 2.5% of trading volume to automatic buy-and-burn of the RAIN token.
Enlivex (Nasdaq: ENLV) reported 2025 audited results with net income $1.23 billion and diluted EPS $25.48, driven by unrealized appreciation in its treasury and treasury-related derivative assets. The company reported $2.31 billion in treasury assets, $1.93 billion shareholders' equity and $30.0 million in cash and short-term digital investments. Enlivex reiterates a dual strategy combining clinical-stage longevity therapeutics and a prediction-markets-backed treasury model and will host a webcast on March 25, 2026 at 09:00 am ET to discuss results.
Enlivex (Nasdaq: ENLV) closed a $21 million debt financing (net proceeds ~$18.7M) on March 23, 2026, via a convertible note at a fixed conversion price of $2.69175 per share. The company acquired $10 million of RAIN tokens and extended an option to buy more RAIN through Dec 31, 2027. The Board approved a $20 million share repurchase program, subject to regulatory requirements.
Transactions support the company’s treasury and repurchase strategy and may affect capital structure and treasury composition.